NCT03729128View on ClinicalTrials.gov

Add-on Low Dose Dextromethorphan and Memantine in Patients With Amphetamine-type Stimulants Use Disorder

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

July 24, 2018

Primary Completion Date

August 31, 2020

Study Completion Date

August 31, 2020

Conditions
Stimulants Use Disorder
Interventions
DRUG

dextromethorphan and memantine (DM+MM)

Patients of Amphetamine-type stimulants use disorder (ATSUD) will take dextromethorphan 30 mg/day and memantine 5 mg/day combination (DM+MM) daily for 12 weeks.

DRUG

Placebos

Patients of Amphetamine-type stimulants use disorder (ATSUD) will take placebos daily for 12 weeks.

Trial Locations (1)

Unknown

National Cheng Kung University Hospital, Tainan City

All Listed Sponsors
collaborator

Ministry of Science and Technology, Taiwan

OTHER_GOV

lead

Tzu-Yun Wang

OTHER

NCT03729128 - Add-on Low Dose Dextromethorphan and Memantine in Patients With Amphetamine-type Stimulants Use Disorder | Biotech Hunter | Biotech Hunter